B
Beate Schultheis
Researcher at Ruhr University Bochum
Publications - 92
Citations - 6324
Beate Schultheis is an academic researcher from Ruhr University Bochum. The author has contributed to research in topics: Imatinib mesylate & Imatinib. The author has an hindex of 35, co-authored 92 publications receiving 5890 citations. Previous affiliations of Beate Schultheis include Imperial College Healthcare & Heidelberg University.
Papers
More filters
Journal ArticleDOI
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Amy V. Jones,Sebastian Kreil,Katerina Zoi,Katherine Waghorn,Claire Curtis,Lingyan Zhang,Joannah Score,Rachel Seear,Andrew Chase,Francis H. Grand,Helen E. White,Christine Zoi,Dimitris Loukopoulos,Evangelos Terpos,Elisavet-Christine Vervessou,Beate Schultheis,Michael Emig,Thomas Ernst,Eva Lengfelder,Rüdiger Hehlmann,Andreas Hochhaus,David Oscier,Richard T. Silver,Andreas Reiter,Nicholas C.P. Cross +24 more
TL;DR: It is concluded that V617F is widespread in MPDs and detection of this acquired mutation is likely to have a major impact on the way patients with MPD are diagnosed, as well as serving as an obvious target for signal transduction therapy.
Journal ArticleDOI
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance
François Xavier Mahon,Michael W. Deininger,Beate Schultheis,Jerome Chabrol,Josy Reiffers,John M. Goldman,Junia V. Melo +6 more
TL;DR: It is concluded that BCR-ABL-positive cells can evade the inhibitory effect of STI571 by different mechanisms, such as Bcr-Abl overexpression, reduced intake mediated by Pgp, and, possibly, acquisition of compensatory mutations in genes other than BCR -ABL.
Journal ArticleDOI
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Jane F. Apperley,Martine Gardembas,Junia V. Melo,Robin Russell-Jones,Barbara J. Bain,E. Joanna Baxter,Andrew Chase,Judith M. Chessells,Marie Colombat,Claire E. Dearden,Sandra Dimitrijevic,François Xavier Mahon,David Marin,Zariana Nikolova,Eduardo Olavarria,Sandra Silberman,Beate Schultheis,Nicholas C.P. Cross,John M. Goldman +18 more
TL;DR: Imatinib mesylate induces durable responses in patients with chronic myeloproliferative diseases associated with activation of PDGFRB and all responses were durable at 9 to 12 months of follow-up.
Journal ArticleDOI
Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells
Letizia Venturini,Karin Battmer,Mirco Castoldi,Beate Schultheis,Andreas Hochhaus,Martina U. Muckenthaler,Arnold Ganser,Matthias Eder,Michaela Scherr +8 more
TL;DR: BCR-ABL- and c-MYC-dependent regulation of miRNA expression in chronic myeloid leukemia (CML) is reported using microarray analysis (miCHIP) and miRNA-specific quantitative real-time reverse transcriptase-polymerase chain reaction (miR-qRT-PCR).
Journal ArticleDOI
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
Dirk Strumberg,Max E. Scheulen,Beate Schultheis,Heike Richly,A. Frost,Martin Büchert,O. Christensen,M Jeffers,R. Heinig,O. Boix,Klaus Mross +10 more
TL;DR: This expanded-cohort phase I study provided the foundation for further clinical trials of regorafenib in patients with metastatic CRC and indicated decreased tumour perfusion in most patients.